-
The traditional Chinese medicine sector has risen significantly, and this individual stock has risen 8 times in the past year
Time of Update: 2023-01-01
It is understood that Guizhou Bailing is a hot stock of CAR-T therapy, traditional Chinese medicine, and innovative drug concept.
It is understood that Guizhou Bailing is a hot stock of CAR-T therapy, traditional Chinese medicine, and innovative drug concept.
-
To achieve import substitution of biopharmaceutical equipment, it is necessary to continuously promote development with quality and innovation
Time of Update: 2023-01-01
To achieve import substitution of biopharmaceutical equipment, it is necessary to promote development with quality and innovation (Image source: Pharmaceutical Network) At present, the development of the biopharmaceutical industry is clearly thriving.
-
Raw materials up to 10,000! 4 consecutive rounds in a week! Many places announced the cancellation of control and the resumption of production and operation! Dozens of chemical raw materials rush high!
Time of Update: 2023-01-01
com" style="margin: 0px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box; overflow-wrap: break-word; ">Source: Waterborne Big PlatformAfter 4 consecutive rounds of rise, global gas prices climbed collectivelyGlobal natural gas prices continue to rise as temperatures continue to drop, resulting in strong demand for natural gas.
-
The concept of ursodeoxycholic acid suddenly became popular, and pharmaceutical companies issued announcements in response
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On December 7, the concept stock of ursodeoxycholic acid broke out across the board, with Sinotherapeutics and Gonggong Pharmaceutical gaining a 20CM price limit, and Shuangcheng Pharmaceutical and Qianhong Pharmaceutical gaining a limit.
-
Capital market A and A are active, and two pharmaceutical companies are "married"!
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];China Resources Sanjiu announced on November 29 that the company will plan to acquire KunYao Group for 2.
js?cdnversion='+~(-new Date()/36e5)];China Resources Sanjiu announced on November 29 that the company will plan to acquire KunYao Group for 2.
-
Under the "hoarding tide", ibuprofen production enterprises have attracted the attention of institutions and investors
Time of Update: 2023-01-01
Rundu shares Rundu replied to investors on November 15 that the company's product ibuprofen sustained-release capsules are suitable for relieving mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea.
-
Listed companies continue to increase share buybacks, and pharmaceutical companies are also setting off a "buyback tide"
Time of Update: 2023-01-01
78 yuan / share, and the total amount of funds paid was 150 million yuan (excluding stamp duty, transaction commissions and other transaction 。 On December 1, CanSino announced that as of November 30, the company had repurchased a total of 670,100 A shares in a centralized bidding transaction, accounting for 0.
-
More than 30 pharmaceutical companies have seen significant shareholder reductions, and these companies have the largest amount of shareholding
Time of Update: 2023-01-01
According to statistics, in November, the directors, supervisors and related persons of listed companies in Shanghai and Shenzhen reduced their holdings by a total of about 5.
-
Pharmaceutical companies have set off a "wave of cooperation", involving new drug research and development, commercialization...
Time of Update: 2023-01-01
Becton Medical has joined forces with NanoString On December 1, medical technology company Becton Medical and NanoString jointly announced that they will start a strategic cooperation in the field of single-cell spatial multiomics, combining the advantages of both parties to provide one-stop technical tools and services for domestic basic scientific research, clinical research and biomedical research and development.
-
Over 1000 bits! What signal does the departure of executives of listed pharmaceutical companies send?
Time of Update: 2023-01-01
(Image source: Pharma Network) Flush data shows that as of November 17, more than 1,400 executives in the A-share biomedical industry left the year, involving 357 enterprises.
-
Ningbo Municipal Supervision Bureau: Fine up to 5 million yuan for manipulating the market price of medical supplies
Time of Update: 2023-01-01
Ningbo Market Supervision WeChat public account news, Ningbo Market Supervision Administration issued the "Reminder on the Price Behavior of Medical Drugs and Supplies" on the 6th. It is proposed that
-
National Action Plan to Curb Microbial Resistance (2022-2025)
Time of Update: 2023-01-01
All provinces, autonomous regions, municipalities directly under the Central Government, and the Xinjiang Production and Construction Corps Health Commission, Education Department (Education Commissi
-
Over $2 billion! Regeneron collaborates with CytomX to develop a new generation of dual antibodies
Time of Update: 2023-01-01
On November 17, Regeneron and CytomX Therapeutics announced a collaboration and license agreement to develop conditionally activated experimental next-generation bispecific cancer therapies using CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform.
-
The improvement of the quality of Chinese medicine pieces still needs to be accelerated, and the upstream pharmaceutical machine industry may be affected
Time of Update: 2023-01-01
In order to strengthen drug quality supervision and ensure the safety of public drug use, local drug regulatory departments are conducting frequent supervision and sampling inspections on the quality
-
On December 5, the pharmaceutical industry received a net purchase of nearly 1.2 billion yuan, and a number of shares received a net purchase of more than 100 million yuan
Time of Update: 2023-01-01
According to the Flush Data Center, Xinhua Pharmaceutical received financing to buy 155 million yuan on December 5, accounting for 18.
On December 5, Tongce Medical received financing to buy 103 million yuan, accounting for 15.
-
Single-use pressure monitoring magnetic positioning radiofrequency ablation catheter approved for marketing
Time of Update: 2023-01-01
The product adopts pressure sensing technology, magnetic field positioning technology, head porous saline perfusion technology and three-dimensional electrophysiological mapping system based on the principle of strain gauges, which can provide an overall solution for the treatment of patients with atrial fibrillation, and is the first cardiac radiofrequency ablation catheter with pressure sensing function in China.
-
The purchase price exceeds $20 billion! Who will this rare disease company "spend"
Time of Update: 2023-01-01
It is understood that Horizon Therapeutics, an innovative pharmaceutical company for rare diseases, announced on November 30 that it was conducting preliminary negotiations with Amgen, Johnson & Johnson (Janssen) and Sanofi on a potential acquisition offer.
-
Announcement of the State Food and Drug Administration on the Implementation of Electronic Declaration of Drug Registration Applications (No. 110 of 2022)
Time of Update: 2022-12-30
In order to improve the efficiency of drug review and approval, the State Food and Drug Administration has decided to implement electronic submission of application materials for drug registration, and the specific requirements are announced as follows:1.
-
Novo Nordisk Shanghai signed a contract with Shanghai Pharmaceutical Holdings The cooperation will achieve another breakthrough
Time of Update: 2022-12-30
Xiaping Zhou, Senior Vice President and President of Greater China, Novo Nordisk, said: "This investment is an important step for Novo Nordisk to realize the new layout of the 'dual center, three engines' whole industry chain, which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients.
-
Nearly 80 bispecific antibodies are in the clinical trial stage, and some pharmaceutical companies have 8 products to tap the market of 100 billion!
Time of Update: 2022-12-30
com, nearly 80 bispecific antibody drugs are currently in the state of clinical application and above research and development, involving pharmaceutical companies such as Innovent Biologics, Pumix Biotechnology, Roche, CSPC Holdings, Johnson & Johnson, etc.
